立他司特滴眼液不良反应有哪些？

Lifitegrast Eye Drops 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED). Although the treatment is effective, it also has adverse effects.

In the 5 DED clinical trials using lifitegrast eye drops, 1401 patients received at least one dose of lifitegrast (1287 of them received lifitegrast 5%). The majority of patients (84%) had treatment exposure of less than or equal to 3 months. 170 patients were exposed to lifitegrast for approximately 12 months. The majority of treated patients were female (77%). The most common adverse reactions reported by 5%-25% of patients were infusion site irritation, taste disturbance, and decreased vision.

Other adverse reactions reported by 1% to 5% of patients with Ritalast eye drops are blurred vision, conjunctival congestion, eye irritation, headache, increased tearing, eye discharge, eye discomfort, eye itching, and sinusitis.

In postmarketing experience, rare cases of severe hypersensitivity reactions, including anaphylactic reactions, bronchospasm, respiratory distress, pharyngeal edema, tongue swelling, urticaria, allergic conjunctivitis, dyspnea, angioedema, and atopic dermatitis, have been reported with Ritalast eye drops. Eye swelling and rash have also been reported.

The most common side effects include eye irritation, discomfort, or blurred vision when the eye drops are applied, and an unusual taste (dysgeusia).

If you develop any symptoms of wheezing, difficulty breathing, or tongue swelling, seek medical attention immediately. These are not all possible side effects of Ritalast Eye Drops. If you have any side effects that bother you, tell your doctor.

Research shows that inflammation is one of the key characteristics of dry eye. Suppressing the inflammatory response of the ocular surface, breaking the inflammatory cycle, and restoring the homeostasis of the ocular surface are important directions in the treatment of dry eye. Ritalast eye drops bind to LFA-1 on the surface of leukocytes, blocking the reaction between LFA-1 and its associated ligand intercellular adhesion molecule-1 (ICAM-1), thereby achieving the purpose of treating dry eye by inhibiting ocular surface inflammation. Ritalast eye drops are currently the only prescription drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of dry eye. It is recommended that patients take medication as directed by their doctor and receive symptomatic treatment.

Recommended related articles: